Work Here?
Overview
Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy by in-licensing and advancing late-stage drug candidates. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights in a deal worth up to $1.1 billion, aimed at improving heart function by tempering myosin activity in HCM. The program includes Phase 2 trials in obstructive and non-obstructive HCM and a Phase 3 trial in China, with global late-stage development planned to begin in 2026. The company differentiates itself by pursuing a best-in-class profile with better efficacy, safety, and dosing, supported by a strong leadership team and high-profile investors, with the goal of delivering an approved therapy that provides meaningful clinical benefit and broader global access.
About Braveheart Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2025
Get referred to Braveheart Bio
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 2026: LIONHEART-HCM sites are activating, and Braveheart expects first dosing this year.
- May 2026 nHCM data supported NOBLEHEART-HCM, with U.S. IND open and Phase 3 planned.
- Camzyos and aficamten validate cardiac myosin inhibition, expanding physician familiarity before Braveheart launches.
What critics are saying
- Bristol Myers Squibb's Camzyos and Cytokinetics' aficamten already occupy the HCM market.
- Braveheart owns one asset; a 2027 Phase 3 miss would wipe out its pipeline.
- The Hengrui license concentrates supply and IP dependence outside China, risking leverage in setbacks.
What makes Braveheart Bio unique
- BHB-1893’s March 2026 Phase 2 showed rapid LVOT gradient reductions with minimal LVEF change.
- Braveheart’s August 2026 IPO raised $439.9 million, funding Phase 3 through 2027.
- Travis Murdoch and Chris Viehbacher bring Biogen-era execution credibility from HI-Bio and Biogen.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$567.5M
Above
Industry Average
Funded Over
2 Rounds
Benefits
Remote Work Options
Flexible Work Hours
Company Equity
Stock Price
Growth & Insights and Company News
6 month growth
↓ -7%1 year growth
↑ 0%2 year growth
↑ 0%Braveheart Bio completed its initial public offering on 7 August 2026, raising $122.8 million in gross proceeds. The biotech company is developing BHB-1893, a drug candidate for treating hypertrophic cardiomyopathy. The IPO significantly strengthened Braveheart Bio's balance sheet. As of 30 June 2026, the company held cash and cash equivalents of $122.8 million, up from $89.2 million at the end of 2025. The company reported a net loss of $18.6 million for the three months ended 30 June 2026, and $32.9 million for the six-month period. Research and development expenses totalled $11.1 million in the second quarter. Braveheart Bio's accumulated deficit stood at $95.9 million as of 30 June 2026. The company has a limited operating history and one product candidate in clinical trials.
Braveheart Bio to participate in Cantor Global Healthcare Conference. SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) - Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the event. About Braveheart Bio Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. Investor Relations Contact Alexander Sharif New Street Investor Relations [email protected]
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3. Biotech correspondent. For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, has priced its upsized initial public offering at $18.00 per share. The San Francisco-based company is offering 21,250,000 shares, with expected gross proceeds of $382.5 million before deducting underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on 6 August 2026 under the ticker symbol "BRVE". The offering is scheduled to close on 7 August 2026, subject to customary closing conditions. Braveheart Bio has granted underwriters a 30-day option to purchase up to an additional 3,187,500 shares. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers.
Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer to lead clinical strategy and medical affairs as the company advances BHB-1893 towards a planned global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026. DeGoma joins from Tourmaline Bio, where he served as Senior Vice President of Medical Research. He previously held leadership positions at Akebia Therapeutics, overseeing cardiovascular outcomes trials with over 7,000 patients, and at ChemoCentryx and Penn Medicine. He completed his cardiovascular medicine fellowship at Stanford University and is a Fellow of the American College of Cardiology. Braveheart Bio is a clinical-stage biotechnology company backed by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences.
Braveheart Bio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Braveheart Bio
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2025
Braveheart Bio is Hiring for 7 Jobs on Simplify!
Find jobs on Simplify and start your career today